Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 4:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 63 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Terminated Phase 1 Interventional Results available

High Dose Vitamin C in Cardiac Surgery Patients

NCT02762331
Conditions
Disorder of Vitamin C, Atrial Fibrillation, Complications Due to Coronary Artery Bypass Graft, Heart Valve Disease
Interventions
Ascorbic Acid, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Vitamin C Deficiency, Smoking, Surgery, Surgery--Complications, Wound, Wound Complication, Wound Infection, Wound Dehiscence, Wound of Skin, Mandible Fracture, Mandible Open Fracture, Mandible Closed Fracture, Mandibular Fractures, Ascorbic Acid Deficiency, Oxidative Stress, Inflammation
Interventions
Vitamin C, Placebo
Dietary Supplement · Other
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Completed Phase 1Phase 2 Interventional Results available

Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients

NCT00469209
Conditions
Myeloma
Interventions
Trisenox (Arsenic Trioxide), Velcade (Bortezomib), Melphalan, Vitamin C (Ascorbic Acid)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Conditions
Cancer
Interventions
Ascorbic Acid
Drug
Lead sponsor
Midwestern Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Zion, Illinois
Conditions
Pancreatic Neoplasms
Interventions
Ascorbate, Gemcitabine, Radiation therapy
Drug · Radiation
Lead sponsor
Joseph J. Cullen
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Hypoxia, Hypercapnia
Interventions
L-NMMA, Ketorolac, Ascorbic Acid, Intravenous Catheter, Transcranial Doppler Ultrasound
Drug · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Bladder Cancer
Interventions
Intravenous ascorbic acid/vitamin C
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Iowa City, Iowa • Kansas City, Kansas
Conditions
Ovarian Cancer
Interventions
Oral Ascorbic Acid, Paclitaxel, Carboplatin, Sodium Ascorbate, Oral Mixed natural Carotenoids with Vitamin A, Vitamin E
Dietary Supplement · Drug
Lead sponsor
Jeanne Drisko, MD, CNS, FACN
Other
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Pancreatic Cancer
Interventions
Intravenous Vitamin C, Gemcitabine
Drug
Lead sponsor
Jeanne Drisko, MD, CNS, FACN
Other
Eligibility
21 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Non-Small-Cell Lung Carcinoma, NSCLC
Interventions
Radiation Therapy, Paclitaxel, Carboplatin, Ascorbic Acid
Drug
Lead sponsor
Joseph J. Cullen, MD, FACS
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Terminated Early Phase 1 Interventional Accepts healthy volunteers

Targeting ER Stress in Vascular Dysfunction

NCT04001647
Conditions
Vasodilation, Arterial Stiffness
Interventions
Acetylcholine, Sodium Nitroprusside, Ascorbic Acid
Drug
Lead sponsor
Colorado State University
Other
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Fort Collins, Colorado
Conditions
Metastatic Hepatocellular Carcinoma, Advanced Liver Cancer
Interventions
Ascorbic Acid + Sorafenib, Sorafenib
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Intravenous Ascorbic Acid

NCT01833351
Conditions
Safety and Pharmacokinetics of Intravenous Ascorbate
Interventions
IV Vitamin C
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
21 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Kansas City, Kansas
Completed Phase 4 Interventional Results available

Phosphate Lowering in CKD Trial

NCT02209636
Conditions
Chronic Kidney Disease, Cardiovascular Disease
Interventions
Lanthanum carbonate, placebo, Ascorbic Acid, Nitroglycerin, Flow-mediated dilation measurement, Aortic pulse-wave velocity, Endothelial cell collection
Drug · Procedure
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 79 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Renal Metabolism of Glycolate to Oxalate

NCT04437225
Conditions
Healthy
Interventions
Low oxalate controlled Diet, Primed, continuous intravenous infusion of 13C2-Glycolate, Bolus intravenous infusion of 13C2-Glycolate, Oral bolus administration of 13C2-Glycolate
Dietary Supplement · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2030
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Myelodysplastic Syndromes and Leukemia, Myeloid, Acute
Interventions
Arsenic Trioxide, Decitabine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Septic Shock, Ascorbic Acid Deficiency
Interventions
Intravenous Ascorbic Acid
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 90 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Stage IV Colorectal Cancer
Interventions
Ascorbic Acid, Irinotecan
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Not applicable Interventional Accepts healthy volunteers Results available

Assessment of Endogenous Oxalate Synthesis

NCT05229952
Conditions
Healthy, Kidney Stone, Obesity
Interventions
Low-oxalate controlled diet, Primed, continuous intravenous infusion of 13C2-oxalate
Dietary Supplement · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Neuroblastoma, Ganglioneuroblastoma
Interventions
Patient Derived CD171 specific CAR T cells expressing EGFRt (2nd generation T cells), Patient Derived CD171 specific CAR T cells expressing EGFRt (3rd generation T cells), Patient Derived CD171 specific CAR T cells expressing EGFRt (long spacer 2nd generation T cells)
Biological
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
18 Months to 26 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2038
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Liver Transplant Failure and Rejection
Interventions
Ascorbic acid, Placebo
Drug · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Bladder Cancer
Interventions
Ascorbic Acid
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
3
States / cities
Fairway, Kansas • Kansas City, Kansas
Completed Phase 3 Interventional Results available

Vitamin C, Thiamine, and Steroids in Sepsis

NCT03509350
Conditions
Sepsis
Interventions
Vitamin C, Thiamine, Hydrocortisone, Vitamin C Placebo, Thiamine Placebo, Hydrocortisone Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
43
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 30 more